

David Back

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5927852/publications.pdf>

Version: 2024-02-01

62
papers

2,715
citations

186209

28
h-index

182361

51
g-index

81
all docs

81
docs citations

81
times ranked

3041
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV Infection. <i>Clinical Pharmacokinetics</i> , 1999, 36, 289-304.	1.6	253
2	Protease Inhibitors in Patients with HIV Disease. <i>Clinical Pharmacokinetics</i> , 1997, 32, 194-209.	1.6	239
3	Therapeutic drug monitoring in HIV infection: current status and future directions. <i>Aids</i> , 2002, 16, S5-S37.	1.0	155
4	Ageing with HIV: medication use and risk for potential drug-drug interactions. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2107-2111.	1.3	131
5	The challenge of HIV treatment in an era of polypharmacy. <i>Journal of the International AIDS Society</i> , 2020, 23, e25449.	1.2	107
6	Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1755-1758.	1.3	102
7	The potential for interactions between antimalarial and antiretroviral drugs. <i>Aids</i> , 2005, 19, 995-1005.	1.0	101
8	Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions. <i>Journal of Hepatology</i> , 2013, 58, 792-800.	1.8	100
9	Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. <i>Clinical Infectious Diseases</i> , 2016, 62, 561-567.	2.9	89
10	Darunavir: Pharmacokinetics and Drug Interactions. <i>Antiviral Therapy</i> , 2008, 13, 1-14.	0.6	80
11	Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2213-2221.	1.3	77
12	An Update on Therapeutic Drug Monitoring for Antiretroviral Drugs. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 468-473.	1.0	75
13	Stopping antiretroviral therapy. <i>Aids</i> , 2007, 21, 1673-1682.	1.0	63
14	Aging in HIV-Infected Subjects: A New Scenario and a New View. <i>BioMed Research International</i> , 2017, 2017, 1-9.	0.9	56
15	Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study. <i>Clinical Pharmacokinetics</i> , 2016, 55, 861-873.	1.6	51
16	Pharmacokinetic Drug Interactions with Nevirapine. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 34, S8-S14.	0.9	50
17	Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3084-3086.	1.3	43
18	Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA). <i>Journal of Infectious Diseases</i> , 2016, 213, 1013-1017.	1.9	40

#	ARTICLE	IF	CITATIONS
19	Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling. <i>Journal of Infectious Diseases</i> , 2019, 219, 1735-1742.	1.9	40
20	Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 555-561.	1.3	35
21	Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions. <i>Annals of Internal Medicine</i> , 2022, 175, 744-746.	2.0	35
22	The importance of drug-drug interactions in the DAA era. <i>Digestive and Liver Disease</i> , 2013, 45, S343-S348.	0.4	32
23	Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study. <i>Clinical Infectious Diseases</i> , 2015, 61, 453-463.	2.9	32
24	Pharmacokinetics of Atazanavir/Ritonavir Once Daily and Lopinavir/Ritonavir Twice and once Daily over 72 h following drug Cessation. <i>Antiviral Therapy</i> , 2008, 13, 901-907.	0.6	32
25	Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. <i>Drugs in R and D</i> , 2021, 21, 9-27.	1.1	31
26	Intracellular Accumulation of Nelfinavir and Its Relationship to P-Glycoprotein Expression and Function in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2004, 9, 115-122.	0.6	31
27	Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1354-9.	1.3	30
28	Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3417-3424.	1.3	30
29	Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1642-1647.	1.3	29
30	The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1027, 174-180.	1.2	29
31	Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. <i>In Silico Pharmacology</i> , 2013, 1, 4.	1.8	26
32	Pharmacokinetics of Once-Daily Saquinavir/Ritonavir in HIV-Infected Subjects: Comparison with the Standard Twice-Daily Regimen. <i>Antiviral Therapy</i> , 2004, 9, 423-429.	0.6	26
33	Efavirenz-but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a subdermal contraceptive implant. <i>Journal of the International AIDS Society</i> , 2014, 17, 19484.	1.2	23
34	Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2816-2822.	1.3	21
35	COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 212-213.	1.1	20
36	Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6080-6086.	1.4	19

#	ARTICLE	IF	CITATIONS
37	Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports. <i>Infectious Diseases and Therapy</i> , 2016, 5, 65-71.	1.8	19
38	Darunavir: pharmacokinetics and drug interactions. <i>Antiviral Therapy</i> , 2008, 13, 1-13.	0.6	19
39	Intracellular Indinavir Pharmacokinetics in HIV-Infected Patients: Comparison with Plasma Pharmacokinetics. <i>Antiviral Therapy</i> , 2003, 8, 191-198.	0.6	19
40	Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with <i>CYP2B6</i> c.516G>T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4511-4518.	1.4	18
41	Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. <i>Clinical Pharmacokinetics</i> , 2017, 56, 409-420.	1.6	18
42	Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 38-42.	1.1	17
43	Safety perspectives on presently considered drugs for the treatment of COVID-19. <i>British Journal of Pharmacology</i> , 2020, 177, 4353-4374.	2.7	17
44	Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa040.	0.4	17
45	Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?. <i>Journal of the International AIDS Society</i> , 2014, 17, 19583.	1.2	14
46	Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1911-1915.	1.3	13
47	Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1373-1383.	1.4	13
48	Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw485.	1.3	12
49	Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±bavirin in hepatitis C virus genotype 1 and 4 infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries. <i>Journal of Viral Hepatitis</i> , 2019, 26, 685-696.	1.0	11
50	Twenty years of boosting antiretroviral agents. <i>Aids</i> , 2015, 29, 2229-2233.	1.0	9
51	Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1513-1516.	1.3	9
52	Limited-Sampling Strategy for the Prediction of Boosted Hard-Gel Saquinavir Exposure at a Dosage of 1000/100 mg Twice Daily in Human Immunodeficiency Virus-Infected Individuals. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 361-367.	1.0	7
53	The intersection of drug interactions and adverse reactions in contemporary antiretroviral therapy. <i>Current Opinion in HIV and AIDS</i> , 2021, 16, 292-302.	1.5	7
54	Lipodystrophy in Patients with HIV-1 Infection: Effect of Stopping Protease Inhibitors on Tnf- α and Tnf-Receptor Levels, and on Metabolic Parameters. <i>Antiviral Therapy</i> , 2004, 9, 879-887.	0.6	6

#	ARTICLE	IF	CITATIONS
55	Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1041-1045.	1.3	5
56	Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-1-infected patients: a population PK approach. <i>Journal of the International AIDS Society</i> , 2014, 17, 19586.	1.2	4
57	Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 961-971.	1.1	3
58	A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1812-5.	1.3	2
59	Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals. <i>HIV Clinical Trials</i> , 2018, 19, 31-37.	2.0	2
60	Drug Interactions in Infectious Diseases, 2nd edn. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 611-611.	1.1	0
61	P187...A phase 1 study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers. <i>Sexually Transmitted Infections</i> , 2015, 91, A78.1-A78.	0.8	0
62	Antiretroviral drug-drug interactions in an era of polypharmacy. <i>Germes</i> , 2019, 9, 123-124.	0.5	0